Skip to content
Screener

Krystal Biotech, Inc. KRYS Unrealized Losses on Investments (Before Tax)

Unrealized Losses on Investments (Before Tax) at other companies

BridgeBio Pharma logo
BridgeBio PharmaBBIO
$6K
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$1.16M+464%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$227K+1,035%

Other financials

Income statement

See full
Revenue$116.4M+31.9%
Operating income$53.7M+48.1%
Net income$55.9M+56.5%
EPS (diluted)$1.83+52.5%

Balance sheet

See full
Cash & equivalents$501.3M+62.4%
Total debt$9.1M-5.7%
Total equity$1.3B+29.7%
Total assets$1.4B+30.0%

Cash flow

See full
Operating cash flow$80.4M+160%
CapEx$7.1M+15.2%
Free cash flow$73.2M+196%

Valuation

See full
Market cap$9.81B+147%
Enterprise value$9.32B+156%
P/E43.6×+16.5×
P/S23.5×+12.4×

Profitability

See full
Operating margin42.8%+10.2pp
Net margin53.9%+16.7pp
FCF margin56.9%+16.5pp

Returns & leverage

See full
Return on equity19.9%+6.0pp
Debt / equity0.0×
Current ratio9.5×-0.2×

Where this comes from

Reported directly by Krystal Biotech, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.

The source filing: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 7:06 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001711279-26-000043
(in thousands)Amortized CostGross Unrealized GainsGross Unrealized (Losses)Aggregate Fair ValueCash and Cash EquivalentsShort-term Marketable Securities(1)Long-term Marketable Securities(2)
Level 1:
Cash and cash equivalents$501,313$501,313$501,313
Subtotal501,313501,313501,313
Level 2:
Corporate bonds229,575125(348)229,352147,36981,983
U.S. government agency securities286,398165(338)286,225174,723111,502
Subtotal515,973290(686)515,577322,092193,485
Total$1,017,286$290$(686)$1,016,890$501,313$322,092$193,485

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Krystal Biotech, Inc.'s unrealized losses on investments (before tax)?
Krystal Biotech, Inc. (KRYS) reported unrealized losses on investments (before tax) of $686K in Q1 2026.
How has Krystal Biotech, Inc.'s unrealized losses on investments (before tax) changed year-over-year?
Krystal Biotech, Inc.'s unrealized losses on investments (before tax) increased by 274.9% year-over-year, from $183K to $686K.
What is the long-term trend for Krystal Biotech, Inc.'s unrealized losses on investments (before tax)?
Over 4 years (2021 to 2025), Krystal Biotech, Inc.'s unrealized losses on investments (before tax) has grown at a -54.1% compound annual growth rate (CAGR), from $180K to $8K.

Ask your AI about Krystal Biotech, Inc.'s unrealized losses on investments (before tax).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude